Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.

Zhe-Yu Hu,Huawu Xiao,Mengjia Xiao,Yu Tang,Jian Sun,Ze-Ming Xie,Quchang Ouyang

Clinical Breast Cancer（2018）

引用 11|浏览3

暂无评分

摘要

ER/PR patients were less likely develop secondary breast and ovarian malignancies, possibly owing to advancements in anti-ER/PR treatment. However, ER/PR patients were more likely to develop colorectal cancer, suggesting a potential screening necessity for these patients.

查看译文

关键词

BC survivors,HR and HER2 subtypes,Subsequent colorectal and thyroid cancer,Subsequent ovary/uteri cancer,Surveillance,Epidemiology, and End Results database

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要